Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3201742 | 0.77 | HSP90AA1 (0.35) | HSP90AA1 | |
| SCHEMBL22402401 | 0.77 | HSP90AA1 (0.35) | HSP90AA1 | |
| SCHEMBL22413865 | 0.73 | HSP90AA1 (0.32) | HSP90AA1 | |
| SCHEMBL16677127 | 0.73 | HSP90AA1 (0.32) | HSP90AA1 | |
| SCHEMBL19307839 | 0.71 | SHBG (0.35) | HSP90AA1 | |
| SCHEMBL31175998 | 0.69 | HDAC8 (0.33) | HSP90AA1 | |
| SCHEMBL31194454 | 0.69 | HDAC8 (0.33) | HSP90AA1 | |
| SCHEMBL6299091 | 0.69 | HSP90AA1 (0.38) | HSP90AA1 | |
| SCHEMBL823816 | 0.67 | TSHR (0.33) | DGAT1 | |
| SCHEMBL7604249 | 0.67 | APLNR (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230372309-A1 | ALPHA-2 ADRENERGIC RECEPTOR ANTAGONIST | KYOTO UNIVERSITY (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20230372309-A1 | ALPHA-2 ADRENERGIC RECEPTOR ANTAGONIST | KYOTO UNIVERSITY (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | BEIJING BAYI SPACE LIQUID CRYSTAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | BEIJING BAYI SPACE LIQUID CRYSTAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| EP-1089984-B1 | NON-YELLOWING PARA-TERTIARY-ALKYL PHENYL SUBSTITUTED TRIAZINE AND PYRIMIDINE ULTRAVIOLET LIGHT ABSORBERS | CYTEC TECH CORP (US) | 2004-10-27 | — | — | EP | disclosed |
| US-6509399-B2 | Radiation resistance; absorber | CYTEC TECHNOLOGY CORP | 2003-01-21 | — | — | US | disclosed |
| US-20020013462-A1 | Non-yellowing part-tertiary-alkyl phenyl substituted triazine and pyrimidine ultraviolet light absorbers | CYTEC INDUSTRIES CORP. | 2002-01-31 | — | — | US | disclosed |
| US-20010031867-A1 | Non-yellowing para-tertiary-alkyl phenyl substituted triazineand pyrimidine ultraviolet light absorbers | CYTEC INDUSTRIES CORP. | 2001-10-18 | — | — | US | disclosed |
| US-6239276-B1 | STABILIZER | CYTEC TECHNOLOGY CORPORATION | 2001-05-29 | — | — | US | disclosed |
| EP-1089984-A1 | NON-YELLOWING PARA-TERTIARY-ALKYL PHENYL SUBSTITUTED TRIAZINE AND PYRIMIDINE ULTRAVIOLET LIGHT ABSORBERS | CYTEC TECHNOLOGY CORP. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067226-A1 | NON-YELLOWING PARA-TERTIARY-ALKYL PHENYL SUBSTITUTED TRIAZINE AND PYRIMIDINE ULTRAVIOLET LIGHT ABSORBERS | CYTEC TECHNOLOGY CORP. (US) | 1999-12-29 | — | — | WO | disclosed |
| US-5674377-A | REDUCING HYDROGEN SULFIDE CONTENT BY ADDING AS SCAVENGER 1,3,5-TRI-TERT-BUTYLHEXAHYDRO-1,3-5-TRIAZINE | NALCO/EXXON ENERGY CHEMICALS, L.P. (US) | 1997-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031867-A1 | Non-yellowing para-tertiary-alkyl phenyl substituted triazineand pyrimidine ultraviolet light absorbers | TERB1, RAD52, ERCC4 | HSP90AA1 2335/4885DGAT1 4544/4885 |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | BCKDK, CYP11B2, HSD17B7 | HSP90AA1 1723/4885DGAT1 3409/4885 |
| US-20230372309-A1 | ALPHA-2 ADRENERGIC RECEPTOR ANTAGONIST | ADRA2A, ADRB2, ADRA2B | HSP90AA1 670/4885DGAT1 3632/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | HSP90AA1 1243/4885DGAT1 3076/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | HSP90AA1 1789/4885DGAT1 2398/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | HSP90AA1 1320/4885DGAT1 2875/4885 |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | TRPM5, TRPM6, TRPM2 | HSP90AA1 4412/4885DGAT1 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.